Global Chimeric Antigen Receptor Cell Therapy Market Report 2024 Edition, Market Size, Share, CAGR, Forecast, Revenue

Get the sample copy of Chimeric Antigen Receptor Cell Therapy Market Report 2024 (Global Edition) which includes data such as Market Size, Share, Growth, CAGR, Forecast, Revenue, list of Chimeric Antigen Receptor Cell Therapy Companies (Amgen Inc, Autolus Therapeutics Plc, Beijing Immunochina Medical Science & Technology Co Ltd, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Co, bluebird bio Inc, CARsgen Therapeutics Ltd, Celgene Corp, Cell Medica Ltd, Cellular Biomedicine Group Inc, Celularity Inc, Celyad SA, Daiichi Sankyo Co Ltd, Fosun Pharmaceutical AG, Gilead Sciences Inc), Market Segmented by Type (Monotherapy, Combination Therapy), by Application (Acute Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma, Transplant Rejection, Channel (Direct Sales, Distribution Channel))

获取2024年全球版嵌合抗原受体细胞疗法市场报告的样本副本，其中包含市场规模、份额、增长率、复合年增长率、预测、收入等数据，并列有嵌合抗原受体细胞疗法公司名单（包括Amgen Inc、Autolus Therapeutics Plc、北京免疫中国医疗科技有限公司、Bellicum Pharmaceuticals Inc、Bristol-Myers Squibb Co、bluebird bio Inc、CARsgen Therapeutics Ltd、Celgene Corp、Cell Medica Ltd、Cellular Biomedicine Group Inc、Celularity Inc、Celyad SA、Daiichi Sankyo Co Ltd、复星制药AG、Gilead Sciences Inc），市场按类型（单药疗法、联合疗法）和应用（急性白血病、非霍奇金淋巴瘤、多发性骨髓瘤、移植排斥）进行细分。